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Background. In rat membranous nephropathy, complement
C5b-9 induces glomerular epithelial cell (GEC) injury and pro-
teinuria, which in some models is partially mediated by eico-
sanoids. In cultured rat GEC, sublytic C5b-9 injures plasma
membranes and releases arachidonic acid (AA) and eicosanoids,
due to activation of cytosolic phospholipase A2 (cPLA2). In this
study, we address the role of protein kinases in cPLA2 activation.
Methods. GEC were stably transfected with cDNAs of wild-type
(wt) cPLA2, and serine
5053alanine mutant (cPLA2-SA505),
which lacks the mitogen-activated protein kinase (MAPK) phos-
phorylation site.
Results. Complement stimulated protein kinase C (PKC) activ-
ity in GEC, and activated p42 (but not p38) MAPK. Overexpres-
sion of either cPLA2-wt or cPLA2-SA505 markedly amplified the
release of [3H]AA by C5b-9. Depletion of PKC blocked the
complement-dependent activation of cPLA2-wt or cPLA2-SA505,
but inhibition of the p42 MAPK pathway had no effect. Epidermal
growth factor was a strong activator of p42 MAPK, but stimulated
PKC activity weakly. Unlike complement, activation of cPLA2-wt
by epidermal growth factor was dependent on PKC, and was
augmented significantly by p42 MAPK. Stable overexpression of
phospholipase C-g1 in GEC amplified C5b-9-induced production
of [3H]inositol phosphates and [3H]diacylglycerol, an endogenous
activator of PKC, and complement stimulated tyrosine phosphor-
ylation of phospholipase C-g1.
Conclusions. C5b-9 induces activation of cPLA2 that is depen-
dent on the diacylglycerol-PKC pathway. The role of p42 MAPK
in cPLA2 activation becomes redundant in the presence of
relatively potent PKC activation.
In many cells, release of arachidonic acid (AA) from the
sn-2 position of phospholipids is the rate-limiting step in
the synthesis of eicosanoids. The major pathway for free
AA production is deacylation of phospholipids by phospho-
lipase A2 (PLA2) [1, 2]. There are several forms of PLA2,
including low molecule mass “secretory” PLA2s, an 85-kDa
cytosolic PLA2 (cPLA2 or type IV), and Ca
21-independent
PLA2s [1–4]. cPLA2 is structurally very distinct from the
other PLA2s, and it is found in the cytosol of many cell
types [2, 3, 5]. Based on the relative specificity of cPLA2 for
AA in the sn-2 position, it has been proposed that the
primary role of cPLA2 may be to release AA for synthesis
of eicosanoids. However, more recent studies suggest that
phospholipid hydrolysis by cPLA2 can also contribute to
cell injury [5–7].
A model of dual regulation of cPLA2 activity has been
proposed [5]. First, an increase in cytosolic Ca21 concen-
tration ([Ca21]i) may lead to translocation of cPLA2 from
cytosol to an intracellular membrane, where cPLA2 would
bind via its N-terminal Ca21-dependent lipid binding do-
main [8–10]. Translocation would facilitate access of
cPLA2 to phospholipid substrate, and subsequently, access
of free AA to metabolism by cyclooxygenase. Second,
enzymatic activity of cPLA2 may be increased through
phosphorylation on serine505 by mitogen-activated protein
kinases (MAPKs) [5–11]. There are at least three parallel
MAPK pathways, the p44/p42 or extracellular signal-regu-
lated kinase (ERK)-1/2 pathway, typically activated by
growth factors, as well as the c-Jun N-terminal kinase
pathway and the p38 kinase pathway, which may be acti-
vated by diverse stimuli including “stress,” such as hyper-
osmolality [12–14]. In the ERK1/2 pathway, activation of
Ras (such as, via receptor tyrosine kinases), leads to the
activation of Raf-1, followed by MAP/ERK kinase (MEK),
which then activates ERKs via dual phosphorylation on
threonine and tyrosine. Raf-1 and/or Ras may also be
downstream targets of protein kinase C (PKC) [12, 13], the
activation of which is often preceded by phospholipase C
(PLC)-induced hydrolysis of phospholipids and production
of 1,2-diacylglycerol (DAG) [15–18]. The ERKs have mul-
tiple potential nuclear and cytoplasmic targets, including
cPLA2 [12, 13]. Activation of p38 kinase is also associated
with threonine and tyrosine phosphorylation, but the full
pathway is only partially understood [5]. One possible
target of p38 kinase is cPLA2 [5]. This dual regulation
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model of cPLA2 activation is, however, not supported by all
studies [5].
Activation of the complement cascade near a cell surface
results in assembly of terminal components, exposure of
hydrophobic domains, and insertion of the C5b-9 mem-
brane attack complex into the lipid bilayer of the plasma
membrane [19, 20]. C5b-9 assembly results in formation of
transmembrane channels or rearrangement of membrane
lipids with loss of membrane integrity. Nucleated cells
require multiple C5b-9 lesions for lysis, while at lower
doses, C5b-9 induces sublytic injury, and various metabolic
effects, which may include a rise in [Ca21]i, alterations in
membrane lipids and proteins, activation of phospho-
lipases, protein kinases and G-proteins, and induction of
growth factors and proliferation [19–25]. In rat membra-
nous nephropathy (passive Heymann nephritis), impair-
ment of glomerular capillary wall permselectivity (protein-
uria) is mediated by antibody and C5b-9 [26, 27]. The
primary target of C5b-9 is the visceral glomerular epithelial
cell (GEC), which suffers noncytolytic injury [26, 27]. C5b-9
also stimulates production of glomerular eicosanoids [28–
30], and thromboxane A2 may enhance proteinuria in
certain models of membranous nephropathy [29–32]. This
effect of thromboxane A2 may be through an increase in
glomerular transcapillary pressure, which appears to be
responsible for a portion of the enhanced urine protein
excretion [33]. By analogy, sublytic C5b-9 injures plasma
membranes in cultured rat GEC [34]. In GEC, sublytic
C5b-9 increases [Ca21]i, [22, 35], activates cPLA2, releases
AA and eicosanoids [6, 35, 36], and stimulates phospho-
lipases C (PLC), which lead to production of inositol
phosphates and DAG [21, 37].
The aim of our studies has been to achieve a better
understanding of phospholipid hydrolysis in experimental
membranous nephropathy, and how this process may con-
tribute to glomerular damage. Our recent studies have
employed well-differentiated GEC in culture, and have
focused on the mechanisms of phospholipase activation,
and AA and eicosanoid metabolism. Endogenous cPLA2
expression in GEC is relatively low [6]. Nevertheless, we
have demonstrated that in GEC extracts, sublytic C5b-9
stably increased cPLA2 activity [6]. In GEC that stably
overexpress wild type (wt) cPLA2 (produced by transfec-
tion), complement induced a gel-mobility shift of cPLA2,
consistent with phosphorylation [6]. Moreover, incubation
of cPLA2-wt-transfected GEC with sublytic C5b-9 acutely
amplified production of free AA and prostaglandin E2, and
exacerbated cytotoxicity, as compared with control or pa-
rental GEC [6, 35]. The amount of cPLA2 activity/protein
in the GEC that overexpress cPLA2-wt was within a
physiological range (for example, comparable to endoge-
nous levels of cPLA2 in Madin-Darby canine kidney cells)
[6], suggesting that the results obtained in these GEC are
biologically-relevant, and that analogous processes occur in
parental GEC, although quantitatively reduced in propor-
tion to the lower levels of endogenous cPLA2 expression.
Surprisingly, C5b-9 did not acutely stimulate the activity of
type IIA secretory PLA2, an enzyme believed to play an
important role in inflammation [6, 35]. By stably expressing
mutant constructs of cPLA2 in GEC, we showed that the
C5b-9-induced release of AA via cPLA2 was dependent on
the presence of the Ca21-dependent lipid binding domain,
and required Ca21 influx and association of cPLA2 with
cellular membranes [35]. These factors were necessary, but
insufficient for release of AA, which also appeared to
require protein kinase activation [35]. In the present study,
we have further examined post-translational mechanisms
for the regulation of cPLA2 activity. We demonstrate that
sublytic complement can stimulate activities of PLC-g1,
PKC and ERK2. PKC stimulates cPLA2 activation and AA
release, however, independently of ERK2.
METHODS
Materials
Tissue culture media and reagents were obtained from
Life Technologies (Burlington, Ontario, Canada), and Col-
laborative Research (Bedford, MA, USA). [3H]AA (100
Ci/mmol), [myo-3H]inositol (20 Ci/mmol), and [g-32P]ATP
(3000 Ci/mmol) were purchased from New England Nu-
clear (Boston, MA, USA). Thin layer chromatography
plates (LK5DF) were obtained from Whatman (Clifton,
NJ, USA). Lipids, phorbol myristate acetate (PMA), stau-
rosporine, 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine
(H-7), anisomycin, thrombin, myelin basic protein (MBP),
MBP(4-14) peptide, and protease inhibitors, were purchased
from Sigma Chemical Co. (St. Louis, MO, USA). PD98059
was purchased from New England Biolabs (Mississauga,
Ontario, Canada). Epidermal growth factor (EGF) was
from Collaborative Research. Electrophoresis and immu-
noblotting reagents were from Biorad Laboratories (Mis-
sissauga, Ontario, Canada). Mouse anti-phosphotyrosine
antibody, PY20, mouse anti-ERK1/2 antibody, and mouse
anti-PLC-g1 antibody were purchased from Transduction
Laboratories (Lexington, KY, USA). Rabbit anti-ERK2
antiserum, rabbit anti-Raf-1, and ATF-2(1-96) were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Plas-
mids pMT2-cPLA2-wt [6, 35] and pMT2-PLC (which con-
tains PLC-g1 cDNA) [38] were kindly provided by Drs. J.D.
Clark and J. Knopf, Genetics Institute (Cambridge, MA,
USA). Plasmid pSG5-cPLA2-SA505 [39] was kindly pro-
vided by Dr. B. Kennedy, Merck Frosst Canada (Pointe
Claire-Dorval, Quebec, Canada). The plasmid pRc/RSV
(which contains the neomycin-resistance gene) was from
Invitrogen Corporation (San Diego, CA, USA). Transfinity
CaPO4 transfection system, and G418 (geneticin) were
from Life Technologies.
Cell culture and transfection
Rat GEC culture and characterization has been pub-
lished previously [6, 34]. Clones of GEC were cultured in
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K1 medium on plastic substratum. GEC were co-trans-
fected with the expression vectors pMT2-cPLA2-wt, pSG5-
cPLA2-SA505, or pMT2-PLC, and pRc/RSV (molar ratio
12.5:1), using a CaPO4 transfection system [6, 35, 38].
Colonies of GEC resistant to G418 were isolated, and
expanded. Stable transfectants were selected for a high
level of cPLA2 or PLC-g1 protein expression, which was
determined by immunoblotting [16]. A clone of GEC
containing only the neomycin-resistance gene was used as a
control (clone neo). Characterization of the GEC clones
that stably overexpress cPLA2-wt protein and PLC-g1
protein (both ;6- to 7-fold above parental or neo GEC)
was published previously [6, 35, 38]. In the present study,
the level of cPLA2-SA505 protein expression in the clone of
GEC stably transfected with cPLA2-SA505 cDNA was
;25% of the cPLA2-wt-transfected cells. An additional
GEC clone that overexpresses cPLA2-wt at ;30% of the
level of the original clone was used in the studies presented
in Figure 4A.
Incubation of glomerular epithelial cells with
complement
The standard protocol involved incubation of GEC in
monolayer culture (35 mm plates) with rabbit anti-GEC
antiserum (10% vol/vol) in modified Krebs-Henseleit
buffer containing 145 mM NaCl, 5 mM KCl, 0.5 mM MgSO4,
1 mM Na2HPO4, 0.5 mM CaCl2, 5 mM glucose, and 20 mM
Hepes, pH 7.4, for 40 minutes at 22°C [16, 20, 33, 34]. GEC
were then incubated with normal human serum (2.5%
vol/vol in Krebs-Henseleit buffer), or with heat-inactivated
(decomplemented) human serum (56°C) in controls, for 40
minutes at 37°C. We have generally used heterologous
complement in order to facilitate studies with complement-
deficient sera, and to minimize possible signaling via com-
plement-regulatory proteins; however, in some experi-
ments, the results were confirmed with homologous (rat)
complement. Sublytic concentrations of complement (#5%
normal human serum) were established previously [6]. In
GEC, complement is not activated in the absence of
antibody [34], antibody does not independently affect free
[3H]AA, and down-regulation of PKC (see below) does not
affect C5b-9 assembly [22].
Assay of protein kinase C activity
PKC activity was measured in situ by monitoring phos-
phorylation of a PKC-specific peptide substrate, MBP(4-14)
[40, 41]. After stimulation, GEC in monolayer culture
(24-well plates) were incubated in 100 ml of buffer contain-
ing 137 mM NaCl, 5.4 mM KCl, 0.3 mM Na2HPO4, 0.4 mM
K2HPO4, 5 mM glucose, 20 mM Hepes, 10 mM MgCl2, 25
mM b-glycerophosphate, 50 mg/ml digitonin, 100 mM
[g-32P]ATP (5 mCi), 2.5 mM CaCl2, 5 mM EGTA, and 100
mM MBP(4–14) peptide, pH 7.2. The peptide substrate was
omitted to determine background radioactivity. After 10
minutes incubation at 30°C, 25 ml of 25% TCA was added,
and the mixture was spotted onto phosphocellulose paper.
The paper was washed with 0.75% phosphoric acid and
acetone, and bound radioactivity was quantitated in a
b-scintillation counter. Background radioactivity was sub-
tracted from total radioactivity of each sample, and results
are expressed as fold increase as compared with control.
The assay was linear with respect to incubation time and
substrate concentration.
Assay of MAPK tyrosine phosphorylation and activity
After stimulation, GEC were scraped from culture
dishes. Lysates (200 to 400 mg protein) were immunopre-
cipitated with mouse anti-ERK1/2 antibody, or nonimmune
IgG in controls. Immunoprecipitates were subjected to
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), and were immunoblotted with anti-ERK1/2
or anti-phosphotyrosine antibodies, as described previously
[42]. An analogous protocol was used to assess p38 or
PLC-g1 phosphorylation [38].
To measure ERK2 activity [42], GEC were scraped from
culture dishes and were solubilized in buffer containing
0.5% Triton X-100, 50 mM b-glycerophosphate, 2 mM
MgCl2, 1 mM dithiothreitol, 20 mM leupeptin, 20 mM pep-
statin, 0.2 mM PMSF, 1 mM Na3VO4, 1 mM EGTA, pH 7.2
(4°C). Proteins (50 to 100 mg) were immunoprecipitated
with rabbit anti-ERK2 antibody (1 hr, 4°C), or nonimmune
IgG in controls (background), followed by absorption with
agarose-coupled protein A (1 hr, 4°C). The immunopre-
cipitates were then mixed with 20 mM MOPS, pH 7.2, 25
mM b-glycerophosphate, 5 mM EGTA, 1 mM Na3VO4, 1 mM
dithiothreitol, 0.5 mg/ml bovine brain MBP, 7.5 mM MgCl2,
and 50 mM [g-32P]ATP (10 mCi). After 10 minutes incuba-
tion at 30°C, the mixture was spotted onto phosphocellu-
lose paper. The paper was washed with 0.75% phosphoric
acid and acetone, and bound radioactivity was quantitated
in a b-scintillation counter. Background radioactivity was
subtracted from total radioactivity of each sample, and
results are expressed as fold increase as compared with
control.
A similar protocol was used to measure p38 kinase
activity, except that rabbit anti-p38 antibody was used for
immunoprecipitation, and the assay mixture contained 25
mM Hepes, pH 7.4, 25 mM b-glycerophosphate, 25 mM
MgCl2, 1 mM Na3VO4, 2 mM dithiothreitol, 0.1 mg/ml
ATF-2(1-96), 50 mM [g-
32P]ATP (5 mCi). Laemmli sample
buffer was added after a 20 minute incubation at 22°C, and
the mixture was subjected to SDS-PAGE and autoradiog-
raphy to determine ATF-2-bound radioactivity. Alterna-
tively, the mixture was spotted onto phosphocellulose pa-
per, and processed as above. The assay was linear with
respect to incubation time.
Measurement of [3H]AA, [3H]DAG and [3H]inositol
phosphates
GEC phospholipids were labeled to isotopic equilibrium
with [3H]AA or [3H]inositol for 48 to 72 hours, as detailed
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previously [6, 21, 36, 37]. Lipids were extracted from cells
and cell supernatants. Methods for extraction and separa-
tion of radiolabeled lipids by thin layer chromatography,
and inositol phosphates by ion-exchange chromatography
have been published previously [6, 21, 36, 37]. Changes in
[3H]DAG have been shown to correlate with changes in
DAG mass [37].
Statistics
Data are presented as mean 6 SEM. The t statistic was
used to determine significant differences between two
groups. One-way analysis of variance was used to deter-
mine significant differences among groups. Where signifi-
cant differences were found, individual comparisons were
made between groups using the t statistic, and adjusting the
critical value according to the Bonferroni method. Two-way
analysis of variance was used to determine significant
differences in multiple measurements between two groups.
RESULTS
Complement activates protein kinases
To determine the mechanism of cPLA2 activation by
C5b-9, we initially studied the effects of complement on the
activities of protein kinases that potentially function up-
stream of cPLA2. Incubation of GEC with sublytic comple-
ment stimulated PKC activity (Fig. 1). This activity in-
creased within 10 minutes of exposure, reached a maximum
at 30 minutes, and was sustained at 60 minutes. To dem-
onstrate that homologous complement could produce anal-
ogous effects to human complement, antibody-sensitized
GEC were incubated with 5% normal rat serum, or heat-
inactivated rat serum in controls. Sublytic rat complement
increased PKC activity by 114 6 6% (P , 0.035, 4
experiments). For comparison, we also studied PKC acti-
vation by the potent exogenous activator, PMA, and EGF,
a major mitogen for GEC [42]. PMA showed a robust effect
on PKC activity, while the effect of EGF was relatively
weak (Fig. 1B). Preincubation of GEC with PMA (2 mg/ml
for 18 to 24 hr) to down-regulate (deplete) PKC, abolished
virtually all basal and stimulated activity in this assay.
In the next series of experiments, we studied the effect of
complement on the activation of MAPKs. Incubation of
GEC with sublytic complement stimulated tyrosine phos-
phorylation of ERK2 (Fig. 2A). Densitometry measure-
ments of phosphotyrosine content in ERK immunoprecipi-
tates in four experiments similar to the representative
immunoblot in Figure 2A showed that complement en-
hanced phosphorylation 2.9 6 0.9-fold of control (P , 0.04
complement vs. control). Complement-stimulated tyrosine
phosphorylation of ERK2 was abolished entirely in PKC-
depleted GEC (result not shown). Tyrosine phosphoryla-
tion of ERK2 by EGF (a classical activator of the ERK
pathway) is presented for comparison (Fig. 2B).
In addition to increasing ERK2 tyrosine phosphoryla-
tion, sublytic complement stimulated ERK2 activity (Table
1). The experiments in Table 1 were carried out in GEC
that overexpress cPLA2-wt, but complement stimulated
ERK2 activity just as effectively in neo (control) GEC.
EGF also stimulated ERK2 activity, although EGF was not
as potent an agonist as complement (Table 1). Other
agonists that stimulated ERK2 activity in GEC included
PMA and thrombin (a GEC mitogen). Depletion of PKC
inhibited complement-stimulated ERK2 activity signifi-
cantly (Table 1). Together with the results of ERK2
tyrosine phosphorylation, these data suggest that comple-
ment-dependent activation of ERK2 is mediated predom-
inantly via PKC, but a component of ERK2 activation may
Fig. 1. Sublytic complement stimulates protein kinase C (PKC) activity.
(A) Glomerular epithelial cells (GEC) that overexpress cytosolic phospho-
lipase A2-wild type (cPLA2-wt) were incubated with anti-GEC antiserum,
and then with 2.5% normal human serum (M) to form C5b-9, or
heat-inactivated serum (L) in controls. Total PKC activity was measured
in situ by monitoring phosphorylation of MBP(4-14). Complement stimu-
lated total PKC activity significantly (P , 0.0001, analysis of variance;
*P , 0.005 vs. control; 3 experiments performed in duplicate). (B) PKC
activity was measured in GEC incubated with or without antibody and
complement (40 min), PMA (250 ng/ml, 40 min, 37°C), and EGF (100
ng/ml, 40 min, 37°C). *P , 0.001 versus control, 1P , 0.05 versus control
(5 to 6 experiments performed in duplicate).
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be PKC-independent. As expected, PKC-depletion inhib-
ited the effect of PMA on ERK2 activity, but did not affect
the stimulation by EGF. Addition of PD98059 [43], which
blocks MEK (the kinase just upstream of ERK2), inhibited
complement-, EGF- and PMA-stimulated ERK2 activity
significantly (Table 1). To obtain further support for the
ability of complement to activate the ERK2 pathway we
studied the activation of Raf-1 (the kinase just upstream of
MEK). Incubation of GEC with complement induced a
gel-mobility shift in Raf-1 (Fig. 2C), which is consistent
with phosphorylation/activation of Raf-1 [44].
In contrast to the ERK2 pathway, complement did not
activate the p38 stress kinase pathway. Incubation of GEC
with sublytic complement did not induce tyrosine phos-
phorylation of p38 (Fig. 3A), and did not stimulate p38
kinase activity (Fig. 3B). To verify that the p38 kinase
pathway could actually be activated in GEC, the cells were
stimulated with either hyperosmolar buffer or with aniso-
mycin. In contrast to complement, hyperosmolality stimu-
lated p38 tyrosine phosphorylation (Fig. 3C), and p38
kinase activity, as monitored by phosphorylation of ATF-2
(Fig. 3D). Similarly, anisomycin stimulated p38 tyrosine
phosphorylation (Fig. 3E). We also measured the effect of
anisomycin on p38 kinase activity, but in these experiments
ATF-2 phosphorylation was assessed by counting the ra-
dioactivity directly (Methods section). Anisomycin stimu-
lated p38 kinase activity 1.3 6 0.1-fold (P , 0.02, 7
experiments). It should also be noted that anisomycin did
not stimulate ERK2 activity, monitored as in Table 1
(0.82 6 0.01-fold, 3 experiments).
C5b-9 activates cPLA2-wt and cPLA2-SA505
The next series of studies focused on the role of protein
kinases in the phosphorylation/activation of cPLA2. We
compared stimulated [3H]AA levels in neo (control) GEC
with GEC that overexpress cPLA2-wt, and with GEC that
overexpress cPLA2-SA505. The cPLA2-SA505 mutant is
lacking the MAPK phosphorylation site, PLS505P [11, 39].
In keeping with prior results, complement stimulated a
marked increase in free [3H]AA in GEC that overexpress
cPLA2-wt, whereas only a small upward trend was evident
in neo GEC (Fig. 4A). Complement also stimulated release
of [3H]AA effectively in GEC that overexpress cPLA2-
SA505 (Fig. 4A), indicating that phosphorylation of
serine505 was not necessary for the activation of cPLA2 by
complement. It was not possible to compare the relative
Fig. 2. (A) Complement stimulates tyrosine phosphorylation of ERK2
(p42). GEC that overexpress cPLA2-wt were incubated with antiserum
and 4% normal serum (NS; to form C5b-9), or heat-inactivated serum
(HIS) in controls (40 min). Cell lysates were immunoprecipitated with
antibody to ERK1/2 (aERK 1), or with nonimmune IgG (2). Immuno-
precipitates were immunoblotted with antibody to phosphotyrosine (aPY)
or ERK1/2. Tyrosine phosphorylation of ERK2 (42-kDa) was enhanced in
the complement-stimulated cells. (B) EGF stimulates tyrosine phosphor-
ylation of ERK2. GEC were incubated with or without EGF (100 ng/ml)
for 30 minutes at 37°C. Cell lysates were processed as in A. (C)
Complement induces a gel-mobility shift in Raf-1. GEC were incubated
with antiserum and 2.5% normal serum or heat-inactivated serum (40
min). Cell lysates were immunoprecipitated with anti-Raf-1 antibody
(aRaf-1 1), or with nonimmune IgG (2). Immunoprecipitates were
immunoblotted with anti-Raf-1 antibody.







Complement 4.07 6 1.62 (5)b 58 6 5 (4)d 91 6 7 (3)d
EGF 1.92 6 0.41 (5)b 0 6 0 (4) 100 (2)
PMA 5.19 6 1.62 (6)c 100 6 0 (3)d 77 6 6 (3)d
Thrombin 2.01 6 0.29 (5)c ND ND
Untreated GEC that overexpress cPLA2-wt were incubated with: (i)
antiserum and 2.5% normal serum (to form C5b-9) or heat-inactivated
serum in controls (40 min); (ii) with or without EGF (100 ng/ml, 60 min,
37°C); (iii) with or without PMA (250 ng/ml, 30 min, 37°C), and (iv) with
or without thrombin (5 units/ml, 30 min, 37°C). Cell lysates were immu-
noprecipitated with anti-ERK2 antibody, and ERK2 activity was measured
by monitoring phosphorylation of MBP. To deplete PKC, GEC were
preincubated with PMA (2 mg/ml) for 18–24 hours. To inhibit MEK, GEC
were preincubated with PD98059 (100 mM) for 30 min. ND is not done.
The number of experiments is shown in parentheses.
a % Inhibition in stimulated, PKC-depleted, or PD98059-treated GEC,
as compared with stimulated, untreated cells.
b P , 0.05
c P , 0.01 stimulated vs. control
d p , 0.005 vs. untreated
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efficacy of cPLA2-wt and cPLA2-SA505 in releasing
[3H]AA because we were not able to overexpress these two
enzymes at identical levels in GEC. Furthermore, while
overexpression of cPLA2-wt amplifies complement-depen-
dent release of [3H]AA, as compared with neo GEC, the
amount of amplification does not correlate closely with the
amount of cPLA2 protein overexpression (determined by
immunoblotting). Thus, in GEC that overexpress cPLA2
enzymes, mechanisms for reacylation of AA may be stim-
ulated, such that amplified increases in free AA reach a
plateau.
In the above studies, normal human serum was employed
as the source of complement. Additional experiments were
performed to verify that the effects of complement on AA
release were actually due to C5b-9 assembly. Incubation of
antibody-sensitized GEC that overexpress cPLA2-wt with
2.5% C8-deficient human serum reconstituted with purified
C8 (40 min) increased free [3H]AA by 348 6 110%, as
compared with C8-deficient human serum alone (P , 0.03,
5 experiments).
Activation of cPLA2 by C5b-9 is dependent on protein
kinase C
Previously, we demonstrated that in GEC overexpressing
cPLA2-wt, complement increased free [
3H]AA to 502 6
Fig. 3. (A) Complement does not induce tyrosine phosphorylation of p38
kinase. GEC that overexpress cPLA2-wt were incubated with antiserum
and 2.5% normal serum (NS), or heat-inactivated serum (HIS) in controls
(40 min). Cell lysates were immunoprecipitated with anti-p38 antibody.
Immunoprecipitates were immunoblotted with antibodies to phosphoty-
rosine (aPY) or p38 (ap38). Tyrosine phosphorylation of p38 was absent.
(B) To measure p38 kinase activity, complement-treated (NS) or control
cell lysates (HIS) were immunoprecipitated with anti-p38 antibody, and
activity was determined by monitoring phosphorylation of ATF-2. There
were no significant differences in ATF-2 phosphorylation. (C) Hyperos-
molality induces p38 tyrosine phosphorylation. GEC were incubated in
hyperosmolar buffer, that is, 700 mM NaCl (HyperO) for 15 minutes at
37°C, or in standard buffer (140 mM NaCl; control). GEC lysates were
treated as in A. (D) Hyperosmolality enhances phosphorylation of ATF-2.
Cell lysates were treated as in B. (E) Anisomycin induces p38 tyrosine
phosphorylation. GEC were incubated with or without 1 mM anisomycin
(Aniso) for 15 minutes at 37°C. Cell lysates were treated as in A.
Fig. 4. (A) Complement stimulates [3H]AA release in GEC that overex-
press cPLA2-wt or cPLA2-SA505. Symbols are: (u) wt; (o) SA505; (s)
neo. [3H]AA-labeled GEC were incubated with anti-GEC antiserum, and
then with 2.5% normal serum (NS; to form C5b-9), or heat-inactivated
serum (HIS) in controls (40 min). Significant differences in free [3H]AA
were present among groups (P , 0.0001, analysis of variance; 5 experi-
ments performed in duplicate). *P , 0.0001, NS versus HIS (wt) and P ,
0.0001 wt versus neo (NS), 1P , 0.0001, NS versus HIS (SA505) and P ,
0.0005 SA505 versus neo (NS). (B) Complement-mediated [3H]AA re-
lease by cPLA2-SA505 is dependent on PKC. Symbols are: (u) SA505; (o)
SA505 (PKC-depleted); (s) neo. To deplete PKC, [3H]AA-labeled GEC
were preincubated for 18 to 24 hours with PMA (2 mg/ml). Untreated or
PKC-depleted GEC that overexpress cPLA2-SA505, and neo GEC were
incubated with antibody and complement as above. Significant differences
in free [3H]AA were present among groups (P , 0.0001, analysis of
variance; 4 experiments performed in duplicate). *P , 0.0001 NS versus
HIS (SA505-untreated) and SA505-untreated versus SA505-PKC-de-
pleted (NS).
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93% of control, but after depletion of PKC, the comple-
ment-induced increase was reduced to 325 6 54% control
(P , 0.005, 5 experiments) [35]. The complement-stimu-
lated release of [3H]AA in GEC that overexpress cPLA2-
SA505 was also reduced after PKC-depletion (Fig. 4B). To
further evaluate the role of protein kinases in cPLA2
activation, we studied the release of [3H]AA in GEC
permeabilized with digitonin at clamped [Ca21]. In keeping
with prior results [35], at 200 nM free Ca21, levels of free
[3H]AA were low in cPLA2-transfected and neo GEC (Fig.
5). Moreover, free [3H]AA was not affected after incuba-
tion of these GEC at 200 nM free Ca21 with PMA (PKC
activator) or EGF (that principally activates ERK2). In
contrast, when free Ca21 was clamped at 1 mM in GEC that
overexpress cPLA2-wt, or cPLA2-SA505, incubation with
PMA stimulated [3H]AA release markedly (Fig. 5, A, B).
There was, however, no significant change in neo GEC
(Fig. 5C), indicating that [3H]AA release was actually
mediated via cPLA2. The effect of PMA (Fig. 5A) was
dependent on PKC, since [3H]AA release in GEC that
overexpress cPLA2-wt was abolished in PKC-depleted cells
(Table 2). In two additional experiments, the protein kinase
inhibitors H-7 (100 mM) or staurosporine (1 mM) inhibited
the effect of PMA by 80% and 77%, respectively, support-
ing a role for PKC in cPLA2 activation.
At 1 mM free Ca21, EGF also stimulated [3H]AA release
in GEC that overexpress cPLA2-wt (Fig. 5), and this action
of EGF was dependent on PKC (Table 2). Moreover, EGF
effectively stimulated [3H]AA release in GEC that overex-
press cPLA2-SA505. This result was unexpected, since we
believed that EGF would activate cPLA2 principally via the
ERK pathway, which leads to phosphorylation on serine505
[11]. There were no statistical differences in the potency of
EGF versus PMA on [3H]AA release, even though in
Figure 5A the mean increase in free [3H]AA appears to be
greater with EGF, as compared with PMA.
Activation of cPLA2 by C5b-9 occurs independently of
MAPKs
Studies presented above showed that the complement-
induced activation of ERK2 was mediated largely through
PKC. Complement also stimulated release of [3H]AA
effectively in GEC that overexpress the cPLA2-SA505
mutant, suggesting that activation of ERK2 was not neces-
sary for the activation of cPLA2 by C5b-9. This conclusion
was further supported by demonstrating that inhibition of
the ERK2 pathway with the MEK inhibitor, PD98059, had
no effect on complement-mediated [3H]AA release by
cPLA2-wt (Table 3). We also determined that the ERK2
pathway is not involved in [3H]AA release at a lower dose
of complement (1% normal serum). In two experiments,
complement stimulated a twofold increase in free [3H]AA,
and this change was unaffected by PD98059.
To further define the role of ERK2, we studied the effect
of PD98059 on PMA- and EGF-induced release of
[3H]AA, using the clamped Ca21 system in permeabilized
GEC that overexpress cPLA2-wt. Similar to complement,
while PMA (250 ng/ml) was a potent activator of PKC and
ERK2, [3H]AA release by PMA was not affected by
PD98059 (Table 4). However, since inhibition of PMA-
stimulated ERK2 activity with PD98059 was incomplete
(Table 1), it is possible that the remaining ERK2 activity
was responsible for [3H]AA release. Thus, we also exam-
ined [3H]AA release at 5 ng/ml PMA, a lower dose at which
Fig. 5. PMA and EGF increase free [3H]AA in GEC that overexpress
cPLA2-wt (A) or cPLA2-SA505 (B), but not neo GEC (C). [
3H]AA-labeled
GEC were incubated with modified Krebs-Henseleit buffer alone (o),
PMA (u; 250 ng/ml, 30 min, 37°C) or EGF (s; 100 ng/ml, 60 min, 37°C).
Then, GEC were permeabilized by incubation for 10 minutes at 37°C in
buffer containing digitonin (37.5 mg/ml) and 200 nM, or 1 mM free Ca21
[35]. (A) Significant differences in free [3H]AA were present among
groups (P , 0.0001, analysis of variance; 4 to 14 experiments performed in
duplicate). *P , 0.0001 EGF or PMA versus untreated (1 mM free Ca21).
(B) Significant differences in free [3H]AA were present among groups
(P , 0.0001, analysis of variance; 4 experiments performed in duplicate).
1P , 0.001 PMA versus untreated, *P , 0.0001 EGF versus untreated (1
mM free Ca21). (C) There were no significant differences (3 experiments
performed in duplicate).
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PKC and ERK2 activities were stimulated 1.5 6 0.2 and
1.6 6 0.2-fold, respectively, and at which PD98059 inhib-
ited the PMA-stimulated ERK2 activity by 100%. In two
experiments, PMA (5 ng/ml, 1 mM free Ca21) increased
free [3H]AA 1.9-fold, and this increase was not affected by
PD98059. These results, together with the ability of PMA
to stimulate AA release via cPLA2-SA505 indicate that
cPLA2 activation is independent of ERK2. In the same
experimental system, the effect of thrombin (5 units/ml, 30
min incubation) on [3H]AA release was similar to the effect
of PMA. In these experiments, free [3H]AA levels were:
control 1.97 6 0.27%, thrombin 3.59 6 0.83% of total
radioactivity (1 mM Ca21; 3 experiments performed in
duplicate). The thrombin-induced increase was not inhib-
ited with PD98059.
In contrast, release of [3H]AA by EGF was inhibited with
PD98059 by ;50% in GEC that overexpress cPLA2-wt
(Table 4), while in GEC that overexpress cPLA2-SA505,
PD98059 had no effect on EGF-stimulated AA release
(120 6 9% of untreated, 4 experiments). These results
suggest that unlike complement and PMA, EGF activated
cPLA2-wt via both ERK2- and non-ERK2-dependent path-
ways. Activation of cPLA2-SA505 by EGF (Fig. 5B) likely
represents the non-ERK2-dependent component.
Although complement did not activate the p38 kinase
pathway, we examined whether stimulation of this pathway
could lead to activation of cPLA2. Activation of p38 by
subjecting GEC to hyperosmolar stress did not stimulate
[3H]AA release (Table 5). Incubation of GEC with 1 mM
anisomycin for 30 minutes had no significant effect on free
[3H]AA (92 6 6% of control, 3 experiments). Thus, the p38
kinase pathway does not activate cPLA2 in GEC.
C5b-9 activates PLC-g1
The final series of experiments addressed signals elicited
by C5b-9 assembly that could lead to activation of PKC and
ERK2. DAG is an endogenous activator of some PKC
isoenzymes, and may be produced by PLC-mediated hydro-
lysis of phospholipids. GEC express PLC-g1 endogenously
at a relatively low level [38]. To establish whether PLC-g1
can be activated by C5b-9, we produced GEC that overex-
press PLC-g1. Compared with neo GEC, incubation of
cells that overexpress PLC-g1 with complement resulted in
an amplification of PLC products, including [3H]inositol
Table 2. Effect of PMA and EGF on free [3H]arachidonic acid (AA):
Role of PKC
Free [3H]AA % total radioactivity
Untreated PKC-depleted
[Ca21] 200 nM 0.36 6 0.08 ND
[Ca21] 1 mM 1.68 6 0.24 0.97
[Ca21] 1 mM 1 PMA 5.76 6 0.67a 0.92 6 0.14b
[Ca21] 1 mM 1 EGF 7.05 6 0.52a 1.63 6 0.23b
To deplete protein kinase C (PKC), glomerular epithelial cells (GEC)
were preincubated for 18–24 hours with phorbol myristate acetate (PMA;
2 mg/ml). Untreated or PKC-depleted GEC that overexpress cytosolic
phospholipase A2-wild type (cPLA2-wt) were labelled with [
3H]AA, and
were incubated with modified Krebs-Henseleit buffer alone, PMA (250
ng/ml, 30 min, 37°C) or EGF (100 ng/ml, 60 min, 37°C). Then, GEC were
permeabilized by incubation for 10 min at 37°C in buffer containing
digitonin (37.5 mg/ml) and 200 nM or 1 mM free Ca21. Significant
differences in free [3H]AA were present among groups (P , 0.0001,
analysis of variance; 5 experiments performed in duplicate, except 2
experiments in 1 mM Ca21, PKC-depleted). ND, not done.
a P , 0.0001 1 mM Ca21 1 PMA or 1 mM Ca21 1 EGF vs. 1 mM Ca21
alone (Untreated)
b P , 0.0001 PKC-depleted vs. untreated
Table 3. PD98059 does not inhibit complement-induced [3H]AA
release
Free [3H]AA % total radioactivity
Untreated PD98059
Complement 4.28 6 1.19a 4.92 6 0.97a
Control 0.89 6 0.11 1.41 6 0.15
GEC that overexpress cPLA2-wt were labelled with [
3H]AA, and were
incubated with 100 mM PD98059 for 30 min, or were untreated. Then,
GEC were incubated with antiserum, and 2.5% normal serum (to form
C5b-9), or heat-inactivated serum in controls (40 min). Significant differ-
ences in free [3H]AA were present among groups (P , 0.01, analysis of
variance; 4 experiments performed in duplicate). There are no significant
differences between Untreated and PD98059.
a P , 0.01 Complement vs. Control
Table 4. Effect of PD98059 on free [3H]AA
Free [3H]AA % total radioactivity
Untreated PD98059
[Ca21] 200 nM 0.49 6 0.15 ND
[Ca21] 1 mM 1.68 6 0.15 ND
[Ca21] 1 mM 1 PMA 5.01 6 0.78 5.41 6 0.78
[Ca21] 1 mM 1 EGF 5.91 6 0.70 3.88 6 0.30a
GEC that overexpress cPLA2-wt were labelled with [
3H]AA, and were
incubated with 100 mM PD98059 for 30 min, or were untreated. Then,
GEC were incubated with buffer alone, PMA (250 ng/ml) or EGF (100
ng/ml) for 30 min at 37°C, and were permeabilized by incubation for 10
min at 37°C in buffer containing digitonin (37.5 mg/ml) and 200 nM or 1
mM free Ca21. Significant differences in free [3H]AA were present among
groups (P , 0.0001, analysis of variance; 5 experiments performed in
duplicate). ND, not done.
a P , 0.01 PD98059 vs. untreated (EGF)




[Ca21] 200 nM 0.53 6 0.11
[Ca21] 1 mM 1.50 6 0.36
[Ca21] 1 mM 1 700 mM NaCl 1.83 6 0.22
[Ca21] 1 mM 1 PMA 3.01 6 1.00
GEC that overexpress cPLA2-wt were labelled with [
3H]AA, and were
incubated with modified Krebs-Henseleit buffer alone, hyperosmolar
buffer (700 mM NaCl), or PMA (250 ng/ml) for 30 min at 37°C. Then,
GEC were permeabilized by incubation for 10 min at 37°C in buffer
containing digitonin (37.5 mg/ml) and 200 nM or 1 mM free Ca21. Addition
of 700 mM NaCl did not increase free [3H]AA significantly (5 experiments
performed in duplicate). Stimulation with PMA is presented for compar-
ison.
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phosphates (Fig. 6A) and [3H]DAG (Fig. 6B), suggesting
that assembly of C5b-9 was coupled to the activation of
PLC-g1. In addition, complement induced tyrosine phos-
phorylation of PLC-g1 (Fig. 7), which correlates with
activation. Densitometry measurements of phosphoty-
rosine content in PLC-g1 immunoprecipitates in six exper-
iments similar to the representative immunoblot in Figure
7 showed that complement increased phosphorylation to
4.6 6 1.6-fold of control (P , 0.025 complement vs.
control). It is likely that endogenous PLC-g1 is activated in
an analogous fashion by complement; however, since the
endogenous enzyme is expressed at a low level, it was not
practical to analyze changes in tyrosine phosphorylation.
[3H]DAG production was further studied in GEC that
express only the endogenous PLC-g1, using different pro-
tocols for C5b-9 assembly. Incubation of antibody-sensi-
tized GEC with 5% normal human serum (40 min) in-
creased [3H]DAG by 207 6 16%, as compared with
heat-inactivated human serum (P , 0.03, 5 experiments).
Incubation of antibody-sensitized cells with 10% C8-defi-
cient human serum (40 min) followed by 2% C6-deficient
rabbit serum (20 min) increased [3H]DAG by 174 6 32%,
as compared with 10% heat-inactivated human serum and
2% C6-deficient rabbit serum (P , 0.02, 4 experiments),
thus confirming that the effect of complement on DAG
production and PLC activation was due to C5b-9 assembly.
Incubation of antibody-sensitized GEC with homologous
complement, that is, 5% normal rat serum (40 min) in-
creased [3H]DAG by 146 6 18%, as compared with
heat-inactivated rat serum (P , 0.025, 4 experiments). It
should also be noted that prolonged incubation of GEC
with PMA abolishes PKC activity, but does not affect
complement-induced production of [3H]DAG (in un-
treated GEC, complement increased [3H]DAG to 165 6
9% of control, while in PKC-depleted cells, the increase
was 225 6 29% of control; 5 experiments). These results
imply that activation of PLC and production of DAG
precede PKC activation.
DISCUSSION
In GEC, assembly of the C5b-9 membrane attack com-
plex releases AA and eicosanoids, and induces plasma
membrane injury. Both of these processes are mediated, at
least in part, through cPLA2 [6, 34, 36]. Sublytic C5b-9
stably enhanced cPLA2 activity in an assay that employed
GEC extracts and exogenous substrate [6]. This in vitro
assay is, however, dependent on the method of substrate
presentation, and does not accurately correlate with
changes in cPLA2 activity in intact cells. To study the role
of cPLA2 in C5b-9-mediated AA release, we developed
Fig. 6. Complement-induced production of [3H]inositol phosphates and
[3H]DAG is mediated by PLC-g1. GEC that overexpress PLC-g1 (u) and
neo GEC (o) were labeled with [3H]inositol (A), or [3H]AA (B). GEC
were incubated with anti-GEC antiserum, and then with 2.5% normal
serum (NS; to form C5b-9), or heat-inactivated serum (HIS) in controls
(40 min). (A) Significant differences in total [3H]inositol phosphates were
present among groups (P , 0.0002; analysis of variance, 5 experiments
performed in duplicate). *P , 0.001 NS versus HIS (PLC-g1) and *P ,
0.02 PLC-g1 versus neo (NS). 1P , 0.03 NS versus HIS (neo). (B)
Significant differences in [3H]DAG were present among groups (P , 0.01;
analysis of variance, 5 experiments performed in duplicate). *P , 0.01 NS
versus HIS (PLC-g1) and *P , 0.02 PLC-g1 versus neo (NS).
Fig. 7. Complement stimulates tyrosine phosphorylation of PLC-g1.
GEC that overexpress PLC-g1 were incubated with anti-GEC antiserum,
and 4% normal serum (NS; to form C5b-9), or heat-inactivated serum
(HIS) in controls (40 min). Cell lysates were immunoprecipitated with
anti-PLC-g1 antibody. Immunoprecipitates were immunoblotted with
antibodies to phosphotyrosine (aPY) or PLC-g1 (aPLC-g1). Tyrosine
phosphorylation of PLC-g1 was enhanced in the complement-stimulated
GEC.
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GEC lines that overexpress cPLA2. Stable overexpression
of cPLA2-wt amplified the effect of C5b-9 on [
3H]AA
release [6] (Fig. 4A). A rise in [Ca21]i, the Ca
21-dependent
lipid binding domain of cPLA2, and membrane association
of cPLA2 were obligatory, but insufficient, for C5b-9-
mediated release of [3H]AA [35]. Thus, our previous
studies suggested that additional regulation was required.
Phosphorylation of cPLA2 enhances enzymatic activity
[5, 11, 45]. Complement induced a gel-mobility shift of
cPLA2-wt, consistent with phosphorylation [6], while down-
regulation or inhibition of PKC reduced complement-
dependent [3H]AA release in GEC that overexpress
cPLA2-wt [35]. In the present study, we have demonstrated
that in GEC, complement stimulated PKC activity (Fig. 1),
and activated the ERK2 pathway (Fig. 2 and Table 1).
Depletion of PKC blocked stimulated ERK2 activity by
;60%, and abolished tyrosine phosphorylation, suggesting
that the majority of ERK2 activation by complement was
PKC-dependent. A smaller portion of the ERK2 activity
may have been stimulated by complement independently of
PKC, and this potential mechanism will require further
study. Inhibition of ERK2 activity, using the MEK inhibi-
tor, PD98059, did not, however, affect the complement-
induced activation of cPLA2 and release of [
3H]AA (Table
3). Further support for the lack of ERK2 involvement in
C5b-9-dependent cPLA2 activation was provided by studies
showing that C5b-9 effectively released [3H]AA via the
cPLA2-SA505 mutant (Fig. 4A). Unlike ERK2, comple-
ment did not activate the p38 kinase pathway (Fig. 3). This
observation was unexpected, since the p38 pathway is
known to be activated by cellular stress, and assembly of the
C5b-9 complex in plasma membranes would likely consti-
tute a stressful stimulus. Thus, the C5b-9-induced activa-
tion of cPLA2 is, at least in part, mediated through PKC,
but is not dependent on ERK2 or p38 kinase (Fig. 8).
Incomplete inhibition of [3H]AA release after PKC deple-
tion suggests involvement of additional pathways, which
will require definition in future studies.
To further evaluate the role of protein kinases in cPLA2
activation, we studied changes in free [3H]AA using PMA
and EGF. The actions of the PKC activator, PMA, were
similar to complement (Fig. 8). At elevated [Ca21]i, PMA
stimulated release of [3H]AA in GEC that overexpress
cPLA2-wt (Fig. 5A), the PMA-induced [
3H]AA release was
dependent on PKC, but not ERK2 (Tables 2 and 4), and
PMA stimulated [3H]AA release effectively in GEC that
overexpress cPLA2-SA505 (Fig. 5B). Several important
differences were evident between the effects of comple-
ment and EGF, which principally activated the ERK2
pathway (Fig. 1 and Table 1). EGF activated PKC weakly
(Fig. 1B), and stimulated ERK2 activity independently of
PKC (Table 1). At elevated [Ca21]i, EGF stimulated a rise
in free [3H]AA in GEC that overexpress cPLA2-wt (Fig.
5A), but unlike complement, this effect was inhibited by
50% with PD98059 (Table 4), indicating that EGF-depen-
dent activation of cPLA2-wt was, in part, mediated via
ERK2 (Fig. 8). A portion of cPLA2-wt activation by EGF
remained ERK2-independent, since PD98059 could not
fully block [3H]AA release (Table 4), despite inhibiting
ERK2 activity by 100% (Table 1). In addition, EGF
induced [3H]AA release in GEC that overexpress cPLA2-
SA505 (Fig. 5B). The pathway responsible for the non-
ERK2-dependent portion of cPLA2 activation is most likely
PKC, since PKC-depletion virtually abolished the EGF-
mediated release of [3H]AA (Table 2), even though EGF
induced only a small increase in PKC activity (Fig. 1B).
Based on these results, it is reasonable to conclude that in
GEC, activation of PKC is necessary for release of [3H]AA
via cPLA2. Relatively potent activation of PKC, such as
with complement or PMA, results in activation of cPLA2-wt
that is dependent only on PKC, and is independent of
ERK2 and serine505 phosphorylation. Thus, even though
the ERK2 pathway is activated, it becomes redundant.
However, when stimulation of PKC is weak, and there is
independent activation of the ERK2 pathway, such as with
EGF, then ERK2 augments the effect of PKC on the
activation of cPLA2.
This scheme of cPLA2 activation in GEC is more com-
plex than the model originally proposed by Lin et al [11].
ERK2 can phosphorylate serine505 and increase cPLA2
activity in vitro [11, 45], and overexpression of cPLA2-
SA505 in Chinese hamster ovary cells fails to enhance
agonist-induced AA release that is seen when cPLA2-wt is
overexpressed [11]. Thus, Lin et al concluded that serine505
phosphorylation by ERK is solely responsible for cPLA2
activation. Other studies have suggested that additional
MAPKs, such as p38, can activate cPLA2 similarly to ERK
[5], although we did not find evidence for this mechanism in
our system (Table 5). In GEC, the mechanism of cPLA2
activation may involve direct phosphorylation by PKC. In
support of this view is the demonstration that purified PKC
can directly phosphorylate cPLA2 and enhance activity in
Fig. 8. Protein kinase pathways involved in cPLA2 activation (see text for
details). C5b-9 and PMA activate cPLA2 via PKC. EGF activates cPLA2
via PKC and ERK2.
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vitro [45]. There appear to be multiple PKC phosphoryla-
tion sites in vitro, some or all of which may be required for
activation [45]. Overexpression of cPLA2 in insect cells and
studies in macrophages have demonstrated that multiple
serines in cPLA2 may be major phosphorylation sites [46,
47]. Thus, extensive mutagenesis analysis of cPLA2 will be
required to characterize the regulation of cPLA2 activity by
PKC in intact cells. Furthermore, the regulatory role of
another intermediary non-MAPK kinase, downstream of
PKC, cannot be excluded entirely.
Since PKC appeared to play a central role in comple-
ment-mediated activation of cPLA2, we examined potential
mechanisms of PKC activation, focusing on the production
of DAG, an endogenous activator of the conventional and
novel PKC isoenzymes [15, 16]. GEC express the PKC-a
conventional isoenzyme, and the d and e novel isoenzymes
[48]. Our ability to deplete virtually all PKC activity and
inhibit [3H]AA release in GEC by prolonged incubation
with PMA suggests that PKC-a and/or d may represent the
relevant PKC activity [16, 48], although the PKC substrate
employed in our assay is favored by PKC-a [41]. Previous
studies demonstrated that sublytic C5b-9 increases DAG
due to activation of inositol lipid- and phosphatidylcholine-
directed PLCs [21, 37]. By an approach analogous to
cPLA2, we stably transfected PLC-g1 into GEC, and we
demonstrated that PLC-g1 overexpression amplified com-
plement-mediated production of [3H]inositol phosphates
and [3H]DAG (Fig. 6). Furthermore, complement induced
tyrosine phosphorylation of PLC-g1 (Fig. 7), consistent
with activation [17, 18]. These results indicate that activa-
tion of the DAG/PKC pathway can be coupled to the
activation of PLC-g1. Further studies are required to
determine how assembly of C5b-9 in the plasma membrane
leads to PLC-g1 activation. Possibly, C5b-9 may recruit and
stimulate non-receptor tyrosine kinase(s), which in turn
could phosphorylate and activate PLC-g1 [49, 50]. We have
not excluded a role for other PLC isoenzymes in comple-
ment-induced DAG production and PKC activation. In
other cells, C5b-9 is reported to activate heterotrimeric
G-proteins [23], which can couple to the activation of
PLC-b isoenzymes [17, 18]; however, expression of PLC-b1
in GEC appears to be low [38].
The activation of protein kinases by C5b-9 has also been
addressed in other studies. C5b-9 was shown to stimulate
phosphorylation of a protein that can be a substrate for
PKC in platelets, and to induce translocation of PKC
activity from cytosolic to particulate fractions in Ehrlich
tumor cells [51, 52]. In a lymphoblastoid B cell line, C5b-9
stimulated production of the PKC activator, DAG [53].
While our study was in progress, Niculescu et al [24]
demonstrated that C5b-9 can activate Ras and the ERK1
pathway in lymphoblastic B cells, and that these events
resulted in the stimulation of [3H]thymidine incorporation.
In GEC, ERK2 activation is necessary, but insufficient for
proliferation [42]. Although we have demonstrated ERK2
activation by complement in GEC, sublytic complement
does not stimulate GEC proliferation (unpublished obser-
vations). Perhaps because GEC are well-differentiated, as
compared with tumor cells, induction of proliferation is
more complex. Nevertheless, activation of ERK2 by com-
plement may potentially induce expression of other genes
in GEC (see below).
The GEC is the target of C5b-9 in experimental mem-
branous nephropathy. Glomeruli of rats with membranous
nephropathy show increased synthesis of eicosanoids [28–
30], and in some models, production of eicosanoids en-
hances glomerular injury (that is, proteinuria), possibly due
to changes in glomerular hemodynamics [29–32]. Activa-
tion of cPLA2 in vivo may facilitate glomerular damage by
providing substrate for eicosanoid synthesis, and by exac-
erbating complement-mediated cytotoxicity. Recent studies
have demonstrated the induction of various genes and/or
proteins during the course of experimental membranous
nephropathy. These include platelet-derived growth factor
B-chain [54], cytochrome b558 [54, 55], and matrix metallo-
proteinase-9 [56]. Activation of pathways that potentially
mediate transcription, such as ERK2, may be necessary for
the induction of these genes. Additional studies will be
required to further define the role of cPLA2 and protein
kinases in complement-mediated glomerular injury.
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Abbreviations used in this article are: AA, arachidonic acid; [Ca21]i,
cytosolic Ca21 concentration; cPLA2, cytosolic phospholipase A2; DAG,
diacylglycerol; EGF, epidermal growth factor; ERK, extracellular signal-
regulated kinase; GEC, glomerular epithelial cell; MAPK, mitogen-
activated protein kinase; MEK, MAP/ERK kinase; PKC, protein kinase C;
PLC, phospholipase C; PMA, phorbol myristate acetate; SDS-PAGE,
sodium dodecyl sulfate-polyacrylamide gel electrophoresis; wt, wild type.
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